One-to-Stop Codon SARS-CoV-2 Attenuation for Rapid Vaccine Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid development of vaccines against emerging pathogens like SARS-CoV-2 is hindered by lengthy development times, making it difficult to respond effectively to outbreaks, and there is a need for a method to produce vaccines in large quantities and of high quality to combat pandemics.
Innovation Solution
A polynucleotide encoding an attenuated SARS-CoV-2 virus is developed, comprising at least 20 one-to-stop codons that are synonymous to natural codons but differ by one nucleotide from a STOP codon, allowing for the production of an attenuated virus that induces an immune response and can be used to create vaccines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine development methods are used, then vaccine quality can be ensured, but development time becomes excessively long
Solution Approach 1:
The patent applies preliminary action by pre-modifying the virus genome with one-to-stop codons before vaccine production. This genetic modification is performed in advance on the SARS-CoV-2 genome, creating an attenuated virus that is safer and faster to develop while maintaining immunogenicity. The one-to-stop codons are strategically placed in the genome beforehand, allowing rapid vaccine development without compromising quality.
2Object-affected harmful factors
If the virus is attenuated using traditional methods, then safety is improved, but virus fitness and immunogenicity may be compromised
Solution Approach 1:
The patent applies local quality by making specific, targeted modifications to the virus genome rather than global changes. The one-to-stop codons are strategically placed at specific locations in the SARS-CoV-2 genome (such as in non-essential regions or with specific codon choices), allowing the virus to be attenuated for safety while preserving critical regions needed for immunogenicity. This localized approach ensures safety without compromising the ability to induce an immune response.
Solution Approach 2:
The patent applies parameter changes by modifying the genetic code parameters of the virus. The one-to-stop codons change the genetic parameters of the virus genome, creating a version that is attenuated (safer) but still capable of replication and immune stimulation. This parameter modification allows tuning of the virus properties to achieve both safety and immunogenicity.
3Speed
If rapid virus identification is achieved, then response time is improved, but vaccine production capability remains insufficient
Solution Approach 1:
The patent applies preliminary action by pre-preparing attenuated virus genomes with one-to-stop codons inserted at strategic locations. This preliminary genetic engineering work is done in advance, so when a new virus strain is identified, the attenuated version can be rapidly produced for vaccine development. This eliminates the need for time-consuming attenuation processes after virus identification, thereby improving both response speed and production capability.
Data Source
AI summary
The invention relates to a polynucleotide encoding an attenuated SARS-CoV-2 or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons. The polynucleotide may comprise further modifications and may be comprised in an attenuated SARS-CoV-2. The invention further relates to methods for production of the polynucleotide and pharmaceutical products, e.g. for medical use.